These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 2298615

  • 1. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
    Zeman EM, Lemmon MJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
    [Abstract] [Full Text] [Related]

  • 2. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991 Jan; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

  • 3. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 4. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
    Zeman EM, Brown JM.
    Int J Radiat Biol; 1991 Jan; 59(1):117-31. PubMed ID: 1671059
    [Abstract] [Full Text] [Related]

  • 5. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
    Brown JM, Lemmon MJ.
    Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM, Hirst VK, Lemmon MJ, Brown JM.
    Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
    [Abstract] [Full Text] [Related]

  • 7. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M, Stevens G.
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [Abstract] [Full Text] [Related]

  • 8. Pre- and post-irradiation radiosensitization by SR 4233.
    Zeman EM, Brown JM.
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
    [Abstract] [Full Text] [Related]

  • 9. Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin.
    Sun JR, Brown JM.
    Radiat Res; 1993 Feb; 133(2):252-6. PubMed ID: 8438067
    [Abstract] [Full Text] [Related]

  • 10. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ, Menke D, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jan 01; 28(1):145-50. PubMed ID: 8270435
    [Abstract] [Full Text] [Related]

  • 12. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun 01; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 13. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
    Brown JM, Lemmon MJ.
    Cancer Res; 1990 Dec 15; 50(24):7745-9. PubMed ID: 2253217
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M.
    J Med Chem; 1995 May 12; 38(10):1786-92. PubMed ID: 7752202
    [Abstract] [Full Text] [Related]

  • 15. Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells.
    Masunaga SI, Ono K, Suzuki M, Nishimura Y, Kinashi Y, Takagaki M, Hori H, Nagasawa H, Uto Y, Tsuchiya I, Sadahiro S, Murayama C.
    Int J Radiat Oncol Biol Phys; 2001 Jul 15; 50(4):1063-72. PubMed ID: 11429234
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI, Brown JM.
    Br J Cancer; 1992 Dec 15; 66(6):1053-8. PubMed ID: 1457345
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
    Stern S, Guichard M.
    Radiother Oncol; 1996 Nov 15; 41(2):143-9. PubMed ID: 9004358
    [Abstract] [Full Text] [Related]

  • 18. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 19. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M.
    Br J Cancer Suppl; 1996 Jul 15; 27():S61-4. PubMed ID: 8763848
    [Abstract] [Full Text] [Related]

  • 20. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
    Yuan X, Tabassi K, Williams JA.
    Radiat Oncol Investig; 1999 Jul 15; 7(4):218-30. PubMed ID: 10492162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.